© 2000 American Heart Association, Inc.
UltraRapid Communications |
Tetrahydrobiopterin Improves Endothelium-Dependent Vasodilation in Chronic Smokers
Evidence for a Dysfunctional Nitric Oxide Synthase
From the Universitäts-Krankenhaus Eppendorf, Abteilung Kardiologie (T.H., C.B., A.W., H.M., S.H., T. Meinertz, T. Münzel), Hamburg, Germany, Institut für Pharmakologie und Toxikologie (B.M.), Graz, Austria.
Correspondence to Thomas Heitzer, MD, Universitäts-Krankenhaus Eppendorf, Abteilung für Kardiologie, Martinistr. 52, 20246 Hamburg, Germany. E-mail heitzer{at}uke.uni-hamburg.de
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Abstract—Conditions associated with impaired nitric oxide (NO) activity and accelerated atherosclerosis have been shown to be associated with a reduced bioavailability of tetrahydrobiopterin (BH4). We therefore hypothesized that BH4 supplementation may improve endothelial dysfunction of chronic smokers. Forearm blood flow (FBF) responses to the endothelium-dependent vasodilators acetylcholine (ACh; 0.75, 1.5, and 3.0 µg/100 mL tissue/min) or serotonin (5-HT; 0.7, 2.1, and 6.3 ng/100 mL tissue/min), to the inhibitor of endothelial nitric oxide synthase (NOS) NG-monomethyl-L-arginine (L-NMMA; 2, 4, and 8 µmol/min), and to the endothelium-independent vasodilator sodium nitroprusside (SNP; 0.1, 0.3, and 1.0 µg/100 mL tissue/min) were measured by venous occlusion plethysmography in controls and chronic smokers. Drugs were infused into the brachial artery, and FBF was measured before and during concomitant intra-arterial infusion of BH4, tetrahydroneopterin (NH4; another reduced pteridine), or the antioxidant vitamin C (6 and 18 mg/min). In control subjects, BH4 had no effect on FBF in response to ACh, 5-HT, and SNP. In contrast, in chronic smokers, the attenuated FBF responses to ACh and 5-HT were markedly improved by concomitant administration of BH4, whereas the vasodilator responses to SNP were not affected. L-NMMA-induced vasoconstriction was significantly reduced in smokers compared with controls, suggesting impaired basal NO bioactivity. BH4 improved L-NMMA responses in smokers while having no effect on L-NMMA responses in controls. Pretreatment with vitamin C abolished BH4 effects on ACh-dependent vasodilation. In vitro, NH4 scavenged superoxide created by the xanthine/xanthine oxidase reaction equipotent like BH4 but failed to modify ACh-induced changes in FBF in chronic smokers in vivo. These data support the concept that in addition to the free radical burden of cigarette smoke, a dysfunctional NOS III due to BH4 depletion may contribute at least in part to endothelial dysfunction in chronic smokers. The full text of this article is available at http://www.circresaha.org.
Key Words: smoking • endothelium • nitric oxide • tetrahydrobiopterin • tetrahydroneopterin
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Endothelial-derived nitric oxide (NO) plays a pivotal role in the regulation of vascular tone and in the maintenance of vascular integrity (for review, see Reference 11 ). Several invasive and noninvasive studies have established endothelial dysfunction in chronic smokers in coronary and peripheral conductance2 3 and resistance vessels4 as well as in isolated veins.5 The precise mechanisms underlying endothelial dysfunction in chronic smokers remain to be established but likely involve oxygen-derived free radicals. Chronic smoking increases the excretion of free radical–catalyzed products of arachidonic acid,6 and in chronic smokers, there is a strong correlation of endothelial dysfunction with autoantibody titers against oxidized LDL.4 Cessation of smoking as well as therapy with antioxidants reduces isoprostane excretion6 and improves endothelial dysfunction,7 8 suggesting that in chronic smokers reduced NO bioactivity is at least in part mediated by increased levels of oxygen-derived free radicals.
Cigarette smoke is known to contain a large number of free radicals and pro-oxidants.9 It remains to be established whether these constituents may cause endothelial dysfunction by damaging the endothelium directly or whether cigarette smoke–induced oxidative stress in turn may activate vascular superoxide–producing enzymes that may further increase the free radical burden to the vasculature in a positive feedback fashion.
Recent experimental and clinical studies demonstrated that administration of tetrahydrobiopterin (BH4) improves endothelial dysfunction in diseases with increased vascular superoxide production such as hypercholesterolemia10 and diabetes mellitus.11 Interestingly, in vitro studies with saphenous veins from chronic smokers showed improved endothelium-dependent relaxation after preincubation with BH4.12 BH4 is a critical cofactor for NO formation and appears to modulate NOS activity by serving as electron donor for the hydroxylation of L-arginine.13 Reduced bioavailability of BH4 has been demonstrated to cause an uncoupling of the endothelial NO synthase (NOS III) thereby generating superoxide instead of NO.14 15 Preliminary experiments indicate that peroxynitrite (ONOO-), which is a major constituent of the gas phase of cigarette smoke, avidly oxidizes BH4 to dihydrobiopterin, leading to impaired endothelial function.16
The primary aim of the present study was to assess whether BH4 could improve basal and stimulated NO activity in chronic smokers. Because BH4 is active only in its reduced form, one has to assume that BH4 deficiency may be due to enhanced oxidative modification of BH4. Because ascorbic acid has been shown to enhance endothelial NO production in a BH4-dependent manner,17 the second objective was to test whether pretreatment with the antioxidant vitamin C is able to modulate the effect of BH4 on endothelial function. Third, we compared the antioxidant effects of the pteridine tetrahydroneopterin (NH4) with BH4 effects in vitro and in vivo to determine whether BH4-induced improvements in forearm blood flow (FBF) in chronic smokers are secondary to its effects as a cofactor on a dysfunctional NOS III or due to its nonspecific antioxidant effects.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Study Population
The total study population included 45 chronic smokers and 13 control subjects. Smokers were included in the study if they had a history of 20 or more pack-years (1 pack-year defined as smoking 20 cigarettes per day for 1 year or the equivalent). Subjects with hypercholesterolemia (LDL cholesterol >75th percentile for age and sex), diabetes mellitus, arterial hypertension, or any other systemic disease predisposing them to endothelial dysfunction were excluded from the study. Further exclusion criteria were current use of antioxidants or vasoactive medication. On the day of the study, smoking was not allowed. The study protocol was approved by the local ethics committee, and informed consent was obtained from each subject.
FBF Measurements
FBF measurements were done by venous plethysmography, as
described recently.4 7
Study Design
Protocol 1: Effects of BH4 on Endothelium-Dependent
and Endothelium-Independent Vasodilation in Control
Subjects and Chronic Smokers
Endothelium-dependent vasodilatation was
assessed in 8 chronic smokers and 8 controls by infusing acetylcholine
(ACh) in increasing concentrations of 0.75, 1.5, and 3.0 µg/100 mL
forearm tissue/min. In another group of 5 smokers and 5 control
subjects, serotonin (5-HT) was used as an
endothelium-dependent vasodilator in increasing doses
of 0.7, 2.1, and 6.3 ng/100 mL forearm tissue/min. These particular
5-HT concentrations have been recently shown to cause increases in FBF
that are in contrast to ACh completely inhibited by NOS III
inhibitor
NG-monomethyl-L-arginine
(L-NMMA), reflecting solely NO-mediated
vasodilation.18 Sodium nitroprusside (SNP) was
infused to assess endothelium-independent vasodilation
(0.1, 0.3, and 1.0 µg/100 mL forearm tissue/min). During concurrent
administration of BH4 (500 µg/min), responses to ACh, 5-HT, and SNP
were established again. BH4 infusion was started 5 minutes before
infusing ACh, 5-HT, or SNP. This dose of BH4 was chosen to reach plasma
concentrations that have been shown to achieve maximal NO
production by NOS III in vitro19 and to improve
endothelium-dependent vasodilation in subjects with
hypercholesterolemia.10 Basal NO
activity was estimated in all subjects by assessment of vasoconstrictor
response to cumulative dose infusion of the NOS III
inhibitor L-NMMA at 2, 4, and 8 µmol/min each dose
for 7 minutes. After a resting period of at least 60 minutes (to
reestablish baseline FBF), BH4 was infused intra-arterially
for a 10-minute period. Subsequently, the cumulative dose response to
L-NMMA was repeated during coinfusion of BH4.
Protocol 2: Effects of BH4 in the Presence of Vitamin C on
Endothelial Dysfunction in Chronic Smokers
Vitamin C is a strong antioxidant capable of scavenging free
radicals. In a previous study, we have demonstrated that short-term
administration of vitamin C could improve
endothelium-dependent vasodilation in chronic
smokers.7 In addition, more recent studies demonstrate
that ascorbic acid improves endothelial dysfunction in
a BH4-dependent manner.17 We therefore tested whether
pretreatment with vitamin C is able to modulate BH4 effects on
endothelial function. In 17 chronic smokers, ACh was
tested during coinfusion with saline or BH4 (500 µg/min),
respectively. After cessation of BH4 infusion (for 30 minutes), the
dose-response curve to ACh was repeated during coinfusion with vitamin
C alone (6 mg/min, n=10 or 18 mg/min, n=7) followed by a combination of
BH4 and vitamin C.
Protocol 3: Effects of NH4 and BH4 on Endothelial
Dysfunction in Chronic Smokers
Reduced pteridines such as BH4 have been shown to be potent
antioxidants and to scavenge in vitro oxygen-derived free
radicals.20 To test whether BH4-induced improvements on
FBF in chronic smokers are due to its specific effects on the uncoupled
NOS III or secondary to its antioxidant properties, we tested in an
additional group of 15 smokers equimolar concentrations (50
µmol/L) of BH4 and NH4 on the ACh dose-response relationship on 2
separate days.
In Vitro Experiments
The antioxidative effects of BH4 and NH4 (1 to 100
µmol/L, respectively) were tested in vitro using lucigenin-enhanced
chemiluminescence as recently described.21 Superoxide was
generated using the xanthine/xanthine oxidase
reaction.22
Drugs
The following substances were infused: ACh (Farmigea S.p.A),
5-HT (Sigma Chemical Co), SNP (Schwarz Pharma), L-NMMA (Calbiochem),
and vitamin C (Sanorell). All drugs were freshly diluted to the desired
concentration by addition of normal saline. BH4 and NH4 (Schircks
Laboratories) were prepared just before administration using
oxygen-free saline.
Statistical Analysis
All values are reported as mean±SEM. Group comparisons with
respect to baseline characteristics were performed by unpaired
t test. To test for differences in the overall dose-response
relationship in response to ACh, 5-HT, SNP, and L-NMMA with and without
vitamin C, BH4, and NH4, a two-way ANOVA for repeated measures was
applied. A value of P<0.05 was considered statistically
significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Subjects
The Table
summarizes the characteristics of the study
population. Control subjects and smokers were matched for age.
|
Effect of BH4 on Endothelium-Dependent and
Endothelium-Independent Vasodilation
ACh responses were blunted in chronic smokers (n=8) compared with
control subjects (n=8, P<0.05). BH4 alone did not change
basal FBF in either smokers (2.9±0.2 versus 3.0±0.3 mL/100 mL/min) or
control subjects (3.1±0.3 versus 3.0±0.3 mL/100 mL/min). There was no
effect of BH4 on mean arterial pressure in either
group. In smokers, concomitant infusion of BH4 increased ACh responses
whereas in control subjects the FBF response to ACh was not modified
(Figure 1). Similar results were obtained
with 5-HT as the endothelium-dependent vasodilator
(Figure 2).
|
|
The FBF response to SNP was not different between control subjects and
chronic smokers and was not modified by BH4 (Figure 3).
|
Effect of BH4 on L-NMMA–Induced Vasoconstriction
Inhibition of NO synthesis by L-NMMA (2, 4, and 8
µmol/min) induced a dose-dependent reduction in FBF in both groups
(P<0.001). In smokers (n=13), however, the L-NMMA–induced
reductions in FBF were significantly less compared with control
subjects (n=13, P<0.05) (Figure 4). Concomitant infusion of BH4
significantly increased the vasoconstrictor response to L-NMMA in
chronic smokers but did not modify L-NMMA responses in control
subjects.
|
Effect of BH4 on Endothelium-Dependent Vasodilation
in the Presence of Vitamin C
In smokers (n=17), BH4 coinfusion significantly augmented
ACh-induced vasodilation (Figures 5A and 5B). Similarly, coinfusion of low and high concentrations of vitamin C
(6 and 18 mg/min, n=10 and n=7, respectively) augmented the ACh blood
flow responses dose dependently.
|
Significant differences in the
overall dose-response relationship versus BH4 treatment.BH4 effects on ACh responses were abolished by pretreatment with vitamin C.
Antioxidative Capacity of BH4 and NH4 In Vitro
BH4 as well as NH4 dose dependently inhibited in vitro
lucigenin-enhanced chemiluminescence generated by the xanthine/xanthine
oxidase reaction. The inhibitory effect on superoxide
production was not significantly different between BH4 and NH4
(Figure 6).
|
Effects of BH4 and NH4 on
Endothelium-Dependent Vasodilation
In smokers (n=15, protocol 3), BH4 significantly augmented
ACh-induced vasodilation whereas NH4 was ineffective (Figure 7).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The present studies demonstrate that in chronic smokers administration of the endothelial NOS III cofactor BH4 improves both basal and stimulated NO-mediated vasodilation. These data suggest that endothelial dysfunction in chronic smokers is at least in part secondary to an absolute or relative deficit in BH4 bioavailability.
With the present studies, we can show an impairment of basal and stimulated NO production in chronic smokers leading to endothelial dysfunction. Using the inhibitor of the NOS III L-NMMA, we found, in agreement with previous observations, a significantly attenuated vasoconstriction in smokers compared with control subjects.23 We also studied the vasodilation during stimulation with the endothelium-dependent vasodilators ACh and 5-HT. 5-HT was chosen in addition to ACh because its action is in contrast to ACh completely inhibited by L-NMMA, therefore reflecting pure NO bioactivity.18 ACh- and 5-HT–induced endothelium-dependent vasodilation were markedly reduced in smokers compared with age-matched control subjects while changes in FBF in response to the endothelium-independent vasodilator SNP were preserved.
The mechanisms underlying endothelial dysfunction in
chronic smokers are multifactorial but likely may be a consequence of
increased oxidative stress. Recent studies revealed increased excretion
of the free radical–catalyzed products of
arachidonic acid such as 8-epi
PGF2
6 in chronic smokers. Cessation of cigarette
smoking as well as the use of antioxidants such as vitamin C, but not
the use of cyclo-oxygenase (COX) inhibitors
such as aspirin, reduced isoprostane excretion, suggesting a free
radical–mediated and not a COX-mediated formation of 8-epi
PGF2.6 Recently, we were able to show a close relation
of autoantibody titers to oxidized LDL– and ACh-induced
endothelium-dependent changes in FBF in chronic smokers
with and without hypercholesterolemia,
suggesting an involvement of oxidized LDL in mediating
endothelial dysfunction in vivo.4 Impaired
endothelial-dependent vasorelaxations were markedly
improved by infusing the antioxidant vitamin C, providing evidence that
vitamin C improves endothelial dysfunction mainly by
directly scavenging oxygen-derived free radicals. Cigarette smoke
contains free radicals and pro-oxidants that may cause damage to the
vascular wall via depleting antioxidants,24 causing
protein peroxidation25 and activation of
phagocyte-platelet-endothelial cell
interactions.26 27 It remains to be established, however,
whether constituents of the cigarette smoke have direct toxic effects
to the vasculature and/or whether these components may activate
vascular superoxide–producing enzymes that may further increase the
free radical burden to the vasculature in a positive feedback
fashion.
Recently, it was demonstrated that BH4 improves endothelium-dependent vasodilation in vivo in patients with hypercholesterolemia.10 BH4 is an important cofactor of the NOS III and appears to contribute to the ability of the enzyme to bind L-arginine. In the absence of BH4, there is an uncoupling of the enzyme, leading to inhibition of NO production and to NOS–mediated superoxide production.14 15 . Interestingly, in vitro studies revealed that BH4 improves endothelial-dependent vasorelaxation of vena saphena from chronic smokers in vitro.12 We therefore postulated that BH4 may also improve endothelial dysfunction in chronic smokers in vivo.
Infusing BH4 in a concentration that has been previously shown to increase basal NO bioactivity in hypercholesterolemic patients10 markedly improved the inhibitory effect of the NOS III inhibitor L-NMMA on basal FBF in chronic smokers while having no effect on L-NMMA responses on FBF in healthy control subjects. Similarly, BH4 improved ACh- and 5-HT–induced vasorelaxations in chronic smokers but did not modify endothelium-dependent vasodilation in age-matched control subjects. These data suggest that decreased basal and stimulated NO bioactivity in chronic smokers is at least in part secondary to reduced BH4 bioavailability.
The mechanisms by which BH4 is improving endothelial dysfunction remain unclear. As pointed out earlier, a recent study by Higman et al12 demonstrated that smoking-induced impairment of NOS III activity in human veins could be reversed by exogenous application of BH4. The authors speculated that aromatic amines absorbed into the circulation from the combustion of tobacco are potent inhibitors of the enzymes involved in the biosynthesis of this important NOS III cofactor.12 Cigarette smoke also contains free radicals such as ·NO and O2·-, which may react with each other to form the strong pro-oxidant ONOO-. Moreover, auto-oxidation of polyhydroxyaromatic compounds such as catechol and 1,4-hydroquinone present in cigarette tar (particulate phase) has been demonstrated to induce superoxide production in lung tissue that in turn could react with ·NO from the gas phase of cigarette smoke to form ONOO-.28 ONOO- has been associated with increased oxidative reactions29 and DNA damage,30 and it may cause a reduction of plasma antioxidants as well. Nitration of tyrosine residues of proteins leads to the production of 3-nitrotyrosine that may be considered as a marker of ONOO--dependent oxidative damage.31 Recent studies revealed increased plasma nitrotyrosine concentrations in chronic smokers compared with nonsmokers.32 Interestingly, preliminary studies using a spectrophotometric assay indicate that ONOO-, and not O2·- or hydrogen peroxide, avidly oxidizes BH4 to dihydrobiopterin. This observation would imply that BH4 oxidation rather than intracellular BH4 depletion may induce NOS III dysfunction, which in turn may be a source of altered endothelium-dependent vasorelaxation in chronic smokers.16
To obtain mechanistic insight into the mechanisms by which BH4 improves
endothelial function (depletion of BH4 levels versus
functional depletion due to oxidation), we tested the effects of BH4 in
chronic smokers in the presence and absence of vitamin C. Recent
preliminary results have indicated that ascorbic acid is able to
enhance endothelial NO production in a
BH4-dependent manner.17 With the present studies, we
found that pretreatment with vitamin C in low and high concentrations
abolished the BH4 effects in chronic smokers, suggesting that
functional depletion of BH4 due to enhanced BH4 oxidation rather than
intracellular BH4 depletion accounts at least in part for
endothelial dysfunction in chronic smokers. A critical
question that must be addressed is whether BH4-induced improvements in
endothelial dysfunction in chronic smokers are
secondary to its effects on the uncoupled NOS III or whether they
simply reflect antioxidant actions described for reduced
pteridines.20 Indeed, by using lucigenin-enhanced
chemiluminescence, we found that BH4 as well as NH4 potently scavenged
superoxide generated in vitro by the xanthine/xanthine oxidase reaction
in a dose-dependent fashion (see Figure 6
).
To address this issue, we infused in a subgroup of 15 chronic smokers equimolar concentrations of BH4 and NH4 and tested the effects on the ACh-induced relationship. In contrast to the significant effects of BH4 on endothelial dysfunction, NH4 failed to modify ACh-induced changes in FBF in chronic smokers. These data suggest that BH4-induced improvements in endothelial dysfunction in chronic smokers reflect a specific effect on NOS III rather than being the consequence of a nonspecific antioxidant action.
The improvement of FBF by BH4 in smokers is smaller compared with the
effects of the antioxidant vitamin C. One has to take into account,
however, that the concentration of vitamin C given is on a molar basis
100-fold higher compared with the BH4 concentration. In addition,
the special purpose of our study was to determine to what extent
endothelial dysfunction in chronic smokers is due to
NOS cofactor deficiency and not to test the effects of BH4 when given
in high concentrations where antioxidant properties may come into
play.
Taken together, the present studies demonstrate that endothelial dysfunction in chronic smokers can be improved using the NOS III cofactor BH4. These data support the concept that in addition to the free radical burden of cigarette smoke, a dysfunctional NOS III due to BH4 depletion possibly as a result of BH4 oxidation may contribute at least in part to endothelial dysfunction in chronic smokers. It remains to be established whether oral treatment with the BH4 precursor sepiapterin is able to ameliorate endothelial dysfunction in chronic smokers.
|
Acknowledgments |
|---|
This study was supported in part by the Deutsche Forschungsgemeinschaft Mu 1079 2/2.
Received December 23, 1999; accepted December 23, 1999.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Münzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide superoxide system. Herz. 1997;22:158–172.[Medline] [Order article via Infotrieve]
2.
Celermajer DS, Adams MR, Clarkson P, Robinson J,
McCredie R, Donald A, Deanfield JE. Passive smoking and impaired
endothelium-dependent arterial dilatation
in healthy young adults. N Engl J Med. 1996;334:150–154.
3.
Zeiher AM, Schachinger V, Minners J. Long-term
cigarette smoking impairs endothelium-dependent
coronary arterial vasodilator function.
Circulation. 1995;92:1094–1100.
4.
Heitzer T, Ylä-Herttuala S, Luoma J, Kurz S,
Münzel T, Just H, Olschewski M, Drexler H. Cigarette smoking
potentiates endothelial dysfunction of forearm
resistance vessels in patients with
hypercholesterolemia: role of oxidized LDL.
Circulation. 1996;93:1346–1353.
5. Higman DJ, Greenhalgh RM, Powell JT. Smoking impairs endothelium-dependent relaxation of saphenous vein. Br J Surg. 1993;80:1242–1245.[Medline] [Order article via Infotrieve]
6.
Reilly M, Delanty N, Lawson JA, FitzGerald GA.
Modulation of oxidant stress in vivo in chronic cigarette smokers.
Circulation. 1996;94:19–25.
7.
Heitzer T, Just H, Münzel T. Antioxidant vitamin
C improves endothelial dysfunction in chronic smokers.
Circulation. 1996;94:6–9.
8.
Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C,
Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated
with dose-related and potentially reversible impairment of
endothelium-dependent dilation in healthy young adults.
Circulation. 1993;88:2149–2155.
9. Church DF, Pryor WA. Free radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect. 1985;64:111–126.[Medline] [Order article via Infotrieve]
10. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, Luscher T, Rabelink T. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest. 1997;99:41–46.[Medline] [Order article via Infotrieve]
11. Pieper GM. Acute amelioration of diabetic endothelial dysfunction with a derivative of the nitric oxide synthase cofactor tetrahydrobiopterin. J Cardiovasc Pharmacol. 1997;29:8–15.[Medline] [Order article via Infotrieve]
12.
Higman DJ, Strachan AM, Buttery L, Hicks RC, Springall
DR, Greenhalgh RM, Powell JT. Smoking impairs the activity of
endothelial nitric oxide synthase in saphenous vein.
Arterioscler Thromb Vasc Biol. 1996;16:546–552.
13. Cosentino F, Luscher TF. Tetrahydrobiopterin and endothelial function. Eur Heart J. 1998;19:G3–G8.
14. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BSS, Karoui H, Tordo P, Pritchard KA Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A.. 1998;95:9220–9225.
15.
Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM.
Generation of superoxide by purified brain nitric oxide synthase.
J Biol Chem. 1992;267:24173–24176.
16. Somers M, Falgui BT, Bech-Laursen J, Harrison DG. Interactions between peroxynitrite and tetrahydrobiopterin as a source of altered endothelium-dependent vascular relaxation in atherosclerosis. Circulation. 1998;98(suppl I):I-735. Abstract.
17. Huang A, Venema RC, Vita JA, Keaney JF. Ascorbic acid enhances endothelial nitric oxide production in a tetrahydrobiopterin-dependent manner. Circulation. 1999;100(suppl I):I-702. Abstract.
18. Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995;346:467–471.[Medline] [Order article via Infotrieve]
19. Chen PF, Tsai AL, Wu KK. Cysteine 99 of endothelial nitric oxide synthase (NOS-III) is critical for tetrahydrobiopterin-dependent NOS-III stability and activity. Biochem Biophys Res Commun. 1995;215:1119–1129.[Medline] [Order article via Infotrieve]
20. Shen R. Inhibition of luminol-enhanced chemiluminescence by reduced pterins. Arch Biochem Biophys. 1993;310:60–63.
21. Skatchkov MP, Sperling D, Hink U, Mulsch A, Harrison DG, Sindermann I, Meinertz T, Munzel T. Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Biochem Biophys Res Commun. 1999;254:319–324.[Medline] [Order article via Infotrieve]
22. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546–2551.
23.
Kiowski W, Linder L, Stoschitzky K, Pfisterer M,
Burckhardt D, Burkart F, Buhler FR. Diminished vascular response to
inhibition of endothelium-derived nitric oxide and
enhanced vasoconstriction to exogenously administered endothelin-1 in
clinically healthy smokers. Circulation. 1994;90:27–34.
24. Frei B. Reactive oxygen species and antioxidant vitamins: mechanisms of action. Am J Med. 1994;97:5S–13S.[Medline] [Order article via Infotrieve]
25. Reznick AZ, Cross CE, Hu ML, Suzuki YJ, Khwaja S, Safadi A, Motchnik PA, Packer L, Halliwell B. Modification of plasma proteins by cigarette smoke as measured by protein carbonyl formation. Biochem J. 1992;286:607–611.
26. Lehr HA, Kress E, Menger MD, Friedl HP, Hübner C, Arfors KE, Messmer K. Cigarette smoke elicits leukocyte adhesion to endothelium in hamsters: inhibition by Cu/Zn SOD. Free Radic Biol Med. 1993;14:573–581.[Medline] [Order article via Infotrieve]
27.
Blache D. Involvement of hydrogen and lipid peroxides
in acute tobacco smoking-induced platelet hyperreactivity.
Am J Physiol. 1995;268:H679–H685.
28.
Yoshie Y, Ohshima H. Synergistic induction of DNA
strand breakage by cigarette tar and nitric oxide.
Carcinogenesis. 1997;18:1359–1363.
29.
Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite
oxidation of sulfhydryls. The cytotoxic potential of superoxide and
nitric oxide. J Biol Chem. 1991;266:4244–4250.
30. Szabo C. DNA strand breakage and activation of poly-ADP ribosyltransferase: a cytotoxic pathway triggered by peroxynitrite. Free Radic Biol Med. 1996;21:855–869.[Medline] [Order article via Infotrieve]
31. Beckman JS, Ye ZY, Anderson PG, Chen J, Accavetti MA, Tarpey MM, White CR. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe Seyler. 1994;375:81–88.[Medline] [Order article via Infotrieve]
32.
Petruzzelli S, Puntoni R, Mimotti P, Pulera N, Baliva
F, Fornai E, Giuntini C. Plasma 3-nitrotyrosine in cigarette smokers.
Am J Respir Crit Care Med. 1997;156:1902–1907.
This article has been cited by other articles:
 |
|
 |
|
  F. Mittermayer, J. Pleiner, G. Schaller, S. Zorn, K. Namiranian, S. Kapiotis, G. Bartel, M. Wolfrum, M. Brugel, J. Thiery, et al. Tetrahydrobiopterin corrects Escherichia coli endotoxin-induced endothelial dysfunction Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1752 - H1757. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Satoh, S. Fujimoto, Y. Haruna, S. Arakawa, H. Horike, N. Komai, T. Sasaki, K. Tsujioka, H. Makino, and N. Kashihara NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy Am J Physiol Renal Physiol, June 1, 2005; 288(6): F1144 - F1152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Li and A. M Shah Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2004; 287(5): R1014 - R1030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Podjarny, G. Hasdan, J. Bernheim, G. Rashid, J. Green, Z. Korzets, and J. Bernheim Effect of chronic tetrahydrobiopterin supplementation on blood pressure and proteinuria in 5/6 nephrectomized rats Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2223 - 2227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ihlemann, C. Rask-Madsen, A. Perner, H. Dominguez, T. Hermann, L. Kober, and C. Torp-Pedersen Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H875 - H882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kirsch, H.-G. Korth, V. Stenert, R. Sustmann, and H. de Groot The Autoxidation of Tetrahydrobiopterin Revisited: PROOF OF SUPEROXIDE FORMATION FROM REACTION OF TETRAHYDROBIOPTERIN WITH MOLECULAR OXYGEN J. Biol. Chem., June 27, 2003; 278(27): 24481 - 24490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Hyndman, S. Verma, R. J. Rosenfeld, T. J. Anderson, and H. G. Parsons Interaction of 5-methyltetrahydrofolate and tetrahydrobiopterin on endothelial function Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2167 - H2172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nasreen, T. Nabika, H. Shibata, H. Moriyama, K. Yamashita, J. Masuda, and S. Kobayashi T-786C Polymorphism in Endothelial NO Synthase Gene Affects Cerebral Circulation in Smokers: Possible Gene-Environmental Interaction Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 605 - 610. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||